NEW
YORK, June 9, 2023 /PRNewswire/ -- Jakubowitz
Law announces that an investigation into potential securities
fraud allegations has commenced on behalf of
shareholders of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
To be contacted by a member of our team, fill out the
form:
https://claimyourloss.com/securities/reata-class-action-loss-submission-form/?id=40550&from=4
Further details on the investigation: On May 10, 2023, Reata issued a press release
announcing its financial results for the first quarter of 2023.
Among other items, Reata announced its decision to discontinue
studies for its kidney disease candidate bardoxolone, which the
Company had previously advanced as one of its lead assets in
partnership with Blackstone Life Sciences and Kyoma Kirin. On this
news, Reata's stock price fell $14.99
per share or 14.23%, to close at $90.38 per share on May
10, 2023.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities
fraud. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/reta-fraud-alert-jakubowitz-law-is-investigating-reata-pharmaceuticals-inc-in-connection-with-potential-violations-of-federal-securities-laws-301846747.html
SOURCE Jakubowitz Law
